delavirdine + zidovudine + indinavir

This drug is a **fixed-dose combination** of three antiretroviral agents: **delavirdine** (a non-nucleoside reverse transcriptase inhibitor), **zidovudine** (a nucleoside reverse transcriptase inhibitor), and **indinavir** (an HIV-1 protease inhibitor). This triple combination is used for the treatment of **HIV-1 infection**. Each agent addresses HIV at different stages of its replication cycle: delavirdine and zidovudine inhibit viral reverse transcriptase via non-competitive and competitive mechanisms, respectively, while indinavir inhibits HIV-1 protease, an enzyme necessary for viral polyprotein cleavage and maturation. The combination is designed to increase antiretroviral efficacy and reduce the risk of resistance, though resistance can still quickly develop if adherence is not high. This specific combination has been studied in clinical trials but is not available as a fixed-dose coformulation product from a single manufacturer; its use represents combination therapy prescribed as three separate drugs[1][3][6].